GLP-1 safety
-
Regulatory Safety Scrutiny and the Multi-Billion Dollar Oral Obesity Duel: The Evolving Clinical Stakes of GLP-1 Therapies
As regulators investigate pancreatitis cases and rare gastrointestinal conditions, Eli Lilly and Novo Nordisk engage in a high-stakes oral obesity market duel.